VivoSeq
Hematology

Transfusional Iron Overload

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Transfusional Iron Overload is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed5 · 83%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Completed·Novartis logoNovartis·Phase 4·NCT00117507·24 enrolled
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
Completed·Novartis logoNovartis·N/A·NCT00466063·108 enrolled
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
Completed·Novartis logoNovartis·Phase 2·NCT00379483·66 enrolled
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Completed·Novartis logoNovartis·Phase 2·NCT00110266·176 enrolled
Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
Completed·HHormozgan University of Medical Sciences·N/A·NCT01369719·138 enrolled
Safety of SP-420 in the Treatment of Transfusional Iron Overload
Terminated·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT04741542·2 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)